

CADTH Reference List

# Tailored Opioid Prescribing After Gynecologic Surgery

January 2021

**Authors:** Thyna Vu, Charlene Argáez

**Cite As:** *Tailored Opioid Prescribing After Gynecologic Surgery*. Ottawa: CADTH; 2020 Jan. (CADTH reference list).

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to [requests@cadth.ca](mailto:requests@cadth.ca)

## Key Messages

- No evidence was identified regarding the clinical effectiveness of tailored opioid prescribing after gynecologic surgery.
- No evidence-based guidelines were identified regarding tailored opioid prescribing after gynecologic surgery.

## Research Questions

1. What is the clinical effectiveness of tailored opioid prescribing after gynecologic surgery?
2. What are the evidence-based guidelines regarding tailored opioid prescribing after gynecologic surgery?

## Methods

### Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE, the Cochrane Database of Systematic Reviews, the international HTA database, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy comprised both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were opioids and gynecologic surgery or procedures. No filters were applied to limit the retrieval to study type. Where possible, retrieval was limited to the human population. The search was also limited to English-language documents published between January 1, 2011 and January 18, 2021. Internet links were provided, where available.

### Selection Criteria

One reviewer screened literature search results (titles and abstracts) and selected publications according to the inclusion criteria presented in Table 1. Full texts of study publications were not reviewed. Open access full-text versions of evidence-based guidelines were reviewed when abstracts were not available.

## References

No relevant health technology assessments, systematic reviews, randomized controlled trials, non-randomized studies, or evidence-based guidelines were identified.

References of potential interest that did not meet the inclusion criteria are provided in Appendix 1.

**Table 1: Selection Criteria**

Criteria	Description
<b>Population</b>	Patients (any age) with gynecological conditions (benign or malignant) requiring removal of the uterus (i.e., hysterectomy)
<b>Intervention</b>	Q1 and 2: Tailored (also known as tiered, reduced, or restrictive) opioid prescribing at discharge following gynecologic open surgery or MIS (e.g., laparoscopic, robotic, vaginal procedures) for total/radical hysterectomy alone or in conjunction with another procedure (e.g., bilateral salpingo-oophorectomy, bilateral pelvic lymph node dissection, para-aortic lymph node dissection)
<b>Comparator</b>	Q1: Standard opioid prescribing at discharge following open surgery or MIS for total/radical hysterectomy alone or in conjunction with another procedure Exclude: Studies comparing MIS vs. open surgery Q2: Not applicable
<b>Outcomes</b>	Q1: Pain level, health-related quality of life, adverse events (e.g., respiratory depression, constipation), risk of opioid dependence or addiction, opioid misuse/diversion, rates of hospital readmission, Q2: Recommendations regarding tailored opioid prescribing after gynecologic surgery (e.g., patient criteria for tailored opioid prescribing, surgical procedures appropriate for tailored opioid prescribing)
<b>Study Designs</b>	Health technology assessments, systematic reviews, randomized controlled trials, non-randomized studies, evidence-based guidelines

MIS = minimally invasive surgery, vs. = versus.

### Health Technology Assessments

No literature was identified.

### Systematic Reviews and Meta-analyses

No literature was identified.

### Randomized Controlled Trials

No literature was identified.

### Non-Randomized Studies

No literature was identified.

### Guidelines and Recommendations

No literature was identified.

## Appendix 1: References of Potential Interest

### Previous CADTH Reports

1. Hafizi D, Featherstone R. Smaller quantity opioid prescribing for acute pain: clinical effectiveness and guidelines (CADTH rapid response report: reference list). Ottawa (ON): CADTH; 2019 Jun: <https://cadth.ca/sites/default/files/pdf/htis/2019/RA1039%20Restriction%20for%20meds%20Final.pdf> Accessed 2021 Jan 21.
2. Marchand DK, Ford C. Codeine for acute pain for urological or general surgery patients: a review of clinical effectiveness (CADTH rapid response report: summary with critical appraisal). Ottawa (ON): CADTH; 2019 Nov: <https://www.cadth.ca/sites/default/files/pdf/htis/2019/RC1201%20Codeine%20for%20Urological%20Pts%20Final.pdf> Accessed 2021 Jan 21. Systematic Reviews and Meta-analyses Alternative Outcome – Patterns of Opioid Use.
3. Johnson CM, Makai GEH. A Systematic review of perioperative opioid management for minimally invasive hysterectomy. *J Minim Invasive Gynecol*. 2019 Feb;26(2):233-243. [Medline](#)

### Randomized Controlled Trials

#### *Unclear Intervention – Type of Hysterectomy Not Specified (Enhanced Recovery After Surgery Programs)*

4. Dickson EL, Stockwell E, Geller MA, et al. Enhanced recovery program and length of stay after laparotomy on a gynecologic oncology service: a randomized controlled trial. *Obstet Gynecol*. 2017 Feb;129(2):355-362. [Medline](#)
5. Kilpio O, Harkki PSM, Mentula MJ, Vaananen A, Pakarinen PI. Recovery after enhanced versus conventional care laparoscopic hysterectomy performed in the afternoon: a randomized controlled trial. *Int J Gynaecol Obstet*. 2020 Dec;151(3):392-398. [Medline](#)

### Non-Randomized Studies

#### *Unclear Intervention – Type of Hysterectomy Not Specified*

6. Hillman RT, Iniesta MD, Shi Q, et al. Longitudinal patient-reported outcomes and restrictive opioid prescribing after minimally invasive gynecologic surgery. *Int J Gynecol Cancer*. 2021 Jan;31(1):114-121. [Medline](#)
7. Glaser GE, Kalogera E, Kumar A, et al. Outcomes and patient perspectives following implementation of tiered opioid prescription guidelines in gynecologic surgery. *Gynecol Oncol*. 2020 May;157(2):476-481. [Medline](#)
8. Mark J, Argentieri DM, Gutierrez CA, et al. Ultrarestrictive opioid prescription protocol for pain management after gynecologic and abdominal surgery. *JAMA Netw Open*. 2018 Dec;1(8):e185452. [Medline](#)

#### *Alternative Outcome – Patterns of Opioid Use*

9. Margolis B, Andriani L, Baumann K, Hirsch AM, Pothuri B. Safety and feasibility of discharge without an opioid prescription for patients undergoing gynecologic surgery. *Obstet Gynecol*. 2020 Dec;136(6):1126-1134. [Medline](#)

#### *Alternative Outcome – Patient Factors Associated With Pain and/or Opioid Use*

10. Brunes M, Habel H, Altman D, Ek M. Risk-factors for continuous long-term use of prescription opioid drugs 3 years after hysterectomy: a nationwide cohort study. *Acta Obstet Gynecol Scand*. 2020 Aug;99(8):1057-1063. [Medline](#)
11. McEntee KM, Crawford KD, Wilson MD, et al. Postoperative opioid prescribing and consumption after hysterectomy: a prospective cohort study. *J Minim Invasive Gynecol*. 2020 Nov 02;S1553-4650(20)31112-2. [Medline](#)
12. Wen X, Kogut S, Aroke H, Taylor L, Matteson KA. Chronic opioid use in women following hysterectomy: patterns and predictors. *Pharmacoepidemiol Drug Saf*. 2020 Apr;29(4):493-503. [Medline](#)
13. Weston E, Raker C, Huang D, et al. Opioid use after minimally invasive hysterectomy in gynecologic oncology patients. *Gynecol Oncol*. 2019 Oct;155(1):119-125. [Medline](#)
14. Wong M, Vogell A, Wright K, Isaacson K, Loring M, Morris S. Opioid use after laparoscopic hysterectomy: prescriptions, patient use, and a predictive calculator. *Am J Obstet Gynecol*. 2019 Mar;220(3):259.e251-259.e211. [Medline](#)
15. As-Sanie S, Till SR, Mowers EL, et al. Opioid prescribing patterns, patient use, and postoperative pain after hysterectomy for benign indications. *Obstet Gynecol*. 2017 Dec;130(6):1261-1268. [Medline](#)
16. Aouad MT, Kanazi GE, Malek K, Tamim H, Zahreddine L, Kaddoum RN. Predictors of postoperative pain and analgesic requirements following abdominal hysterectomy: an observational study. *J Anesth*. 2016 Feb;30(1):72-79. [Medline](#)

17. Al-Hashimi M, Scott S, Griffin-Teall N, Thompson J. Influence of ethnicity on the perception and treatment of early post-operative pain. *Br J Pain*. 2015 Aug;9(3):167-172. [Medline](#)
18. Janda AM, As-Sanie S, Rajala B, et al. Fibromyalgia survey criteria are associated with increased postoperative opioid consumption in women undergoing hysterectomy. *Anesthesiology*. 2015 May;122(5):1103-1111. [Medline](#)
19. Ahmed A, Khan F, Ali M, Haqnawaz F, Hussain A, Azam SI. Effect of the menstrual cycle phase on post-operative pain perception and analgesic requirements. *Acta Anaesthesiol Scand*. 2012 May;56(5):629-635. [Medline](#)

### ***Alternative Outcome – Surgery Type on Pain and/or Opioid Use***

20. Wright JD, Huang Y, Melamed A, et al. Use and misuse of opioids after gynecologic surgical procedures. *Obstet Gynecol*. 2019 Aug;134(2):250-260. [Medline](#)
21. Pokkinen SM, Kalliomaki ML, Yli-Hankala A, Nieminen K. Less postoperative pain after laparoscopic hysterectomy than after vaginal hysterectomy. *Arch Gynecol Obstet*. 2015 Jul;292(1):149-154. [Medline](#)

### ***Alternative Outcome – Robot-Assisted Versus Conventional Surgery on Pain and/or Opioid Use***

22. Rajadurai VA, Tan J, Salfinger SG, Cohen PA. Outcomes in women undergoing robotic-assisted laparoscopic hysterectomy compared to conventional laparoscopic hysterectomy at a tertiary hospital in Western Australia. *Aust N Z J Obstet Gynaecol*. 2018 Aug;58(4):443-448. [Medline](#)
23. Westermann LB, Crisp CC, Mazloomdoost D, Kleeman SD, Pauls RN. Comparative perioperative pain and recovery in women undergoing vaginal reconstruction versus robotic sacrocolpopexy. *Female Pelvic Med Reconstr Surg*. 2017 Mar/Apr;23(2):95-100. [Medline](#)
24. Turner TB, Habib AS, Broadwater G, et al. Postoperative pain scores and narcotic use in robotic-assisted versus laparoscopic hysterectomy for endometrial cancer staging. *J Minim Invasive Gynecol*. 2015 Sep-Oct;22(6):1004-1010. [Medline](#)
25. Betcher RE, Chaney JP, Lacy PR, Otey SK, Wood DJ. Analysis of postoperative pain in robotic versus traditional laparoscopic hysterectomy. *J Robot Surg*. 2014 Mar;8(1):35-41. [Medline](#)
26. Leitao MM, Jr., Malhotra V, Briscoe G, et al. Postoperative pain medication requirements in patients undergoing computer-assisted ("Robotic") and standard laparoscopic procedures for newly diagnosed endometrial cancer. *Ann Surg Oncol*. 2013 Oct;20(11):3561-3567. [Medline](#)

### ***Alternative Intervention – Patient Education and Shared Decision-Making***

27. Vilkins AL, Sahara M, Till SR, et al. Effects of shared decision making on opioid prescribing after hysterectomy. *Obstet Gynecol*. 2019 Oct;134(4):823-833. [Medline](#)

### ***Unclear Intervention – Type of Hysterectomy Not Specified (Enhanced Recovery After Surgery Programs)***

28. Lehman A, Kemp EV, Brown J, et al. Pre-emptive non-narcotic pain medication before minimally invasive surgery in gynecologic oncology. *J Minim Invasive Gynecol*. 2020 Jul 27;S1553-4650(20)30353-8. [Medline](#)
29. Movilla PR, Kokroko JA, Kotlyar AG, Rowen TS. Postoperative opioid use using enhanced recovery after surgery guidelines for benign gynecologic procedures. *J Minim Invasive Gynecol*. 2020 Feb;27(2):510-517. [Medline](#)
30. Smith AE, Heiss K, Childress KJ. Enhanced recovery after surgery in pediatric and adolescent gynecology: a pilot study. *J Pediatr Adolesc Gynecol*. 2020 Aug;33(4):403-409. [Medline](#)
31. Weston E, Noel M, Douglas K, et al. The impact of an enhanced recovery after minimally invasive surgery program on opioid use in gynecologic oncology patients undergoing hysterectomy. *Gynecol Oncol*. 2020 May;157(2):469-475. [Medline](#)
32. Hillman RT, Sanchez-Migallon A, Meyer LA, et al. Patient characteristics and opioid use prior to discharge after open gynecologic surgery in an enhanced recovery after surgery (ERAS) program. *Gynecol Oncol*. 2019 Jun;153(3):604-609. [Medline](#)
33. Schwartz AR, Lim S, Broadwater G, et al. Reduction in opioid use and postoperative pain scores after elective laparotomy with implementation of enhanced recovery after surgery protocol on a gynecologic oncology service. *Int J Gynecol Cancer*. 2019 Jun;29(5):935-943. [Medline](#)
34. Trowbridge ER, Evans SL, Sarosiek BM, et al. Enhanced recovery program for minimally invasive and vaginal urogynecologic surgery. *Int Urogynecol J*. 2019 Feb;30(2):313-321. [Medline](#)

35. Bergstrom JE, Scott ME, Alimi Y, et al. Narcotics reduction, quality and safety in gynecologic oncology surgery in the first year of enhanced recovery after surgery protocol implementation. *Gynecol Oncol*. 2018 Jun;149(3):554-559. [Medline](#)
36. Meyer LA, Lasala J, Iniesta MD, et al. Effect of an enhanced recovery after surgery program on opioid use and patient-reported outcomes. *Obstet Gynecol*. 2018 Aug;132(2):281-290. [Medline](#)

## Guidelines and Recommendations

### *Alternative Population – Not Specific to Patients With Gynecological Conditions*

37. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. *J Pain*. 2016 Feb;17(2):131-157. [Medline](#)

### *Unclear Methodology and Alternative Population – Not Specific to Patients With Gynecological Conditions*

38. MN Health Collaborative. Call to action: adult opioid postoperative prescribing. Minneapolis (MN): ICSI; 2019 Sep. [https://www.icsi.org/wp-content/uploads/2019/09/Opioid-PostOp-CTA\\_Final-090519.pdf](https://www.icsi.org/wp-content/uploads/2019/09/Opioid-PostOp-CTA_Final-090519.pdf) Accessed 2021 Jan 21. See: Background and Principles (p.2-3); Recommendations: Postoperative Opioid Prescribing (p.4-5)
39. Pain Management Best Practices Inter-Agency Task Force. Pain management best practices inter-agency task force report: updates, gaps, inconsistencies, and recommendations (*final report*). Washington, D.C.: U.S. Department of Health and Human Services; 2019 May. <https://www.hhs.gov/sites/default/files/pmtf-final-report-2019-05-23.pdf> Accessed 2021 Jan 21. See: 2.1 Approaches to Pain Management – Gaps and Recommendations (p.22); 2.2 Medication – Gaps and Recommendations (p.28-29)

### *Recommendations Not Specified in Abstract*

40. Nelson G, Bakkum-Gamez J, Kalogera E, et al. Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendation-2019 update. *Int J Gynecol Cancer*. 2019 May;29(4):651-668. [Medline](#)

## Review Articles

41. Azari L, Santoso JT, Osborne SE. Optimal pain management in total abdominal hysterectomy. *Obstet Gynecol Surv*. 2013 Mar;68(3):215-227. [Medline](#)

## Additional References

42. CDC. Acute pain: postsurgical Pain. Centers for Disease Control and Prevention (CDC); 2020 May. <https://www.cdc.gov/acute-pain/postsurgical-pain/> Accessed 2021 Jan 19. See: Type III ☒ Expected Longer Term Recovery